Skip to content

Haemonetics HAE Current Debt

Current Debt at other companies

Abbott logo
AbbottABT
$4.41B+771%
TFX
TeleflexTFX
$103.13M+3.1%
Medtronic logo
MedtronicMDT
$1.79B-37.8%
LivaNova logo
LivaNovaLIVN
$121K-99.8%
ICU Medical logo
ICU MedicalICUI
$18.75M-60.8%
Danaher logo
DanaherDHR
$923M+84.2%

Other financials

Income statement

See full
Revenue$346.4M+4.8%
Gross profit$198.2M+2.7%
Operating income$67.4M+14.2%
Net income$44.7M+19.3%
EPS (diluted)$0.95+28.4%

Balance sheet

See full
Cash & equivalents$245.4M-20.0%
Total debt$1.3B-0.7%
Total equity$796.3M-3.0%
Total assets$2.4B-2.2%

Cash flow

See full
Operating cash flow$70.9M-39.1%
CapEx$17.7M+12.9%
Free cash flow$53.3M-47.2%

Valuation

See full
Market cap$3.37B-18.0%
Enterprise value$4.4B-12.5%
P/S2.5×-0.5×

Profitability

See full
Gross margin59%+4.0pp
Operating margin19%+5.9pp
Net margin13.3%+3.8pp
FCF margin19.5%+9.1pp

Returns & leverage

See full
Return on equity19.3%+5.2pp
Debt / equity1.6×0.0×
Current ratio+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtCurrent.

The official record: Haemonetics’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's current debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Haemonetics's current debt?
Haemonetics (HAE) reported current debt of $5.02M in Q1 2026.
How has Haemonetics's current debt changed year-over-year?
Haemonetics's current debt decreased by 98.3% year-over-year, from $303.56M to $5.02M.
What is the long-term trend for Haemonetics's current debt?
Over 5 years (2021 to 2026), Haemonetics's current debt has grown at a -21.7% compound annual growth rate (CAGR), from $17.02M to $5.02M.
What does current debt mean?
The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.